# Catestatin improves glucose homeostasis and insulin sensitivity in diet-induced obese mice

> **NIH VA I01** · VA SAN DIEGO HEALTHCARE SYSTEM · 2020 · —

## Abstract

Project Summary.
Obesity represents a state of chronic, low-grade tissue inflammation that contributes to insulin resistance (IR)
steatosis and type 2 diabetes mellitus (T2DM). The demands for effective therapy call for improved
understanding of the disease. There is a significant gap in our understanding of the endogenous factors that
regulate both inflammatory responses and insulin sensitivity. In this application, we showed that a peptide,
catestatin (CST), derived from a gene product, chromogranin A (CgA), directly improves lipid disposal and
inflammation leading to reversal of insulin resistance (IR) in a mouse model of obesity. CST improved IR in
diet-induced obese (DIO) mice without weight loss. We generated CST-deficient knockout (CST-KO) mice,
which are obese and insulin resistant in normal chow diet. As a possible mechanism, our data suggested that
CST raised AMP levels by inhibiting AMP-deaminase (AMPD), stimulated AMP-dependent Kinase (AMPK)
signaling and AKT phosphorylation in DIO liver as well as in hepatocyte cultures, signifying a direct CST effect.
This activation of AMPK and AKT signaling by CST suppresses gluconeogenesis via phosphorylation of
CRTC2 and FoxO1 and elevates glycogen production via activation of phosphoglucomutase (PGM). Another
consequence of CST action is to attenuate inflammation, mediated by macrophages, in an AMPK-dependent
manner. This is accomplished by suppressing cytokine production and proinflammatory signaling, which in
turn, could enhance AKT signaling. Analysis by transmission electron microscopy (TEM) of the sections of liver
and adipose tissue of DIO mice after CST treatment indicated diminished infiltration or recruitment of
proinflammatory macrophages. We hypothesize that CST inhibits activity of AMPD2 giving rise to elevated
level of AMP, and activation of AMPK, which in turn, reduces steatosis and macrophage-mediated
inflammation leading to enhancement of insulin signaling and suppression of gluconeogenesis in DIO and
CST-KO mice. We will verify our hypothesis by working with two specific aims: Aim I. To test whether CST
suppresses hepatic glucose production through activation of AMPK via inhibition of AMP-deaminase 2
(AMPD2) which elevates AMP levels necessary for AMPK activation. In this aim, we will examine the
mechanism of CST action in liver and hepatocyte focusing on AMPK and PGM activation. Aim II. To test the
hypothesis that CST-mediated activation of AMPK leads to suppression of inflammation and glucose
production via enhancement of AKT signaling in DIO and CST-KO mice. In this aim, we will analyze the
pathways invoked by CST-mediated AMPK activation that lead to suppression of inflammation and glucose
production. We will execute these specific aims by knocking down activities of AMPD2 and AMPKα and
analyzing their impacts on CST mediated signaling, AMP/ATP ratio, PGM activity, cytokine and glucose
production. Through investigation with this proposal, we believe we will discover a novel...

## Key facts

- **NIH application ID:** 9815462
- **Project number:** 5I01BX003934-03
- **Recipient organization:** VA SAN DIEGO HEALTHCARE SYSTEM
- **Principal Investigator:** SUSHIL K MAHATA
- **Activity code:** I01 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2020
- **Award amount:** —
- **Award type:** 5
- **Project period:** 2017-10-01 → 2021-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9815462

## Citation

> US National Institutes of Health, RePORTER application 9815462, Catestatin improves glucose homeostasis and insulin sensitivity in diet-induced obese mice (5I01BX003934-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9815462. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*